Literature DB >> 8745824

[Severe parvovirus B19 infection in an immunocompetent child with hemophilia A].

E Coumau1, J Peynet, M Harzic, G Béal, S Castaigne, G Leverger, P Foucaud.   

Abstract

BACKGROUND: B19 parvovirus is a widespread virus whose typical manifestations in immunocompetent children are erythema infectiosum, acute erythroblastopenia and fetal anemia. CASE REPORT: An 11 year-old immunocompetent patient with hemophilia A was referred for an hemorrhagic syndrome. Forty days after a pasteurized coagulation factor concentrates treatment, and after 12 days of treatment with solvent/detergent factor VIII concentrates, he developed fever, consciousness disorders, pancytopenia, liver cytolysis and probably minor haemophagocytic syndrome, associated with human parvovirus B19 infection. His clinical state returned to normal within 15 days. A retrospective study revealed that the patient had received every day for 12 days, one parvovirus B19 polymerase chain reaction positive batch before the occurrence of symptoms.
CONCLUSION: This case highlights the possibility of severe parvovirus B19 infection transmitted by clotting factors prepared from large pools of plasma. The use of recombinant factors would allow to reduce human virus contamination, even if immune risk has to be more accurately assessed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8745824     DOI: 10.1016/s0929-693x(96)80006-6

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  2 in total

1.  Parvovirus B19 - Revised.

Authors:  Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

Review 2.  The need for continuing vigilance: addressing the threat for transmission of blood-borne infectious disease.

Authors:  Samuel L Stanley
Journal:  Semin Hematol       Date:  2006-04       Impact factor: 3.851

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.